Navigation Links
Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
Date:8/25/2009

col, instead of current therapies which require multiple treatments by physicians or patients either on a daily or weekly basis for up to 20 weeks. We look forward to reviewing the MATRIX study's complete data set." (Click here to see selected information from Cardium's May 14, 2009 webcast or visit the Investor section at Cardium's website at www.cardiumthx.com).

Observational Safety and Efficacy Insights

Based on a continuing review of safety information, the Excellarate product candidate appears to be both safe and well-tolerated, with no serious adverse events attributed to use of the study product.

With respect to efficacy, while the study remains blinded until all key data are collected and fully analyzed, the Company and investigators are encouraged by several observations related to wound healing in the enrolled patient population. First, a number of study investigators have observed very rapid reductions in ulcer area after initial treatment (whereas the ulcers had not substantially reduced in size during a prior 2-week run-in period that was used to screen all patients entering the study). These findings are similar to what had been observed in the Phase 1/2 study.

In addition, the current blinded pooled data set, which includes patients that received the Excellarate product candidate or standardized therapy (placebo or standard of care) is also encouraging. In particular, based on a comparative review of multiple, well documented protein-based wound healing studies, three key efficacy measures: Wound Closure Incidence (percent of patients achieving complete closure over time), Wound Closure Efficiency (per
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
(Date:8/29/2014)...  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... to release its financial results for the fiscal 2014 ... market trading ends on Tuesday, September 9, 2014. ... 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014 ... the Company,s financial results, commercial partnerships, and future outlook.  ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... 2011 Express Scripts (Nasdaq: ESRX ), one ... announced today its intention to release its third quarter earnings ... will hold its quarterly conference call to discuss third quarter ... Time (8:30 a.m. Central Time). This call is ...
... U.S. Food and Drug Administration has issued a proposed ... classification for external pacemaker pulse generators from Class III ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) External pacemaker pulse generators are ... permanent pacemaker can be implanted. They are also used ...
Cached Medicine Technology:FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 2FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 3
(Date:9/1/2014)... 01, 2014 An operating theatre or ... for performing surgical operations. An operating room comprises a ... booms, operating room lights, imaging displays as well as ... by Transparency Market Research, a U.S.-based market research firm, ... USD 4.5 billion by 2019. , According to ...
(Date:9/1/2014)... September 2014: Daily fruit consumption cuts the risk of ... research presented at ESC Congress today by Dr Huaidong ... year follow-up study of nearly 0.5 million people in ... people ate, the more their risk of CVD declined. ... (IHD) and stroke, is the leading cause of death ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... September 01, 2014 Ontraport , ... marketers that was developed to automate the small intricacies ... attention of Shane Michaels, prompting an investigative review. ... daily duty of managing all of the small details ... quite overwhelming,” reports Michaels. “That’s why Ontraport has become ...
(Date:9/1/2014)... Aliso Viejo, California (PRWEB) September 01, 2014 ... of a new tutorial video for the ProWorld Plugin from ... what Final Cut Pro X can do and users now ... own HDRI images.” Said Christina Austin, CEO of Pixel Film ... a definite game changer.” , Learn how to turn a ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2
... (HealthDay News) -- Scientists say they,ve learned why a ... bland supermarket variety. The University of Florida researchers ... heirloom varieties, most of which were bred before today,s ... large chemical diversity. The researchers than had ...
... News) -- Women with advanced breast cancer who have higher ... women with lower levels of fitness during treatment, new research ... and lung function, according to the study by researchers at ... years after treatment has ended. Among those with advanced ...
... News) -- Only one in 14 Hispanic adults in the ... fewer than the one in four whites screened, a new ... insurance and poorer access to health care services are major ... Cancer Institute of New Jersey. They added that their ...
... from the University of California, San Diego and its ... in new grants from the California Institute for Regenerative ... spinal cord injuries, repairing gene mutations that cause amyotrophic ... failure and Alzheimer,s disease. The awards mark the ...
... An overactive BAALC gene in acute leukemia cells identifies patients ... This study discovered why the gene is often overactive., ... guide therapy in these patients. COLUMBUS, Ohio ... overactivating a gene linked to poor treatment response in people ...
... YORK, May 25, 2012 Ben-Gurion University of the ... the desert with the successful application of a solar-powered ... regions. The project was made possible with support from ... The solar-powered system uses nanofiltration membranes to treat the ...
Cached Medicine News:Health News:Fitness May Boost Survival for Women With Breast Cancer 2Health News:Few U.S. Hispanics Screened for Skin Cancer 2Health News:UC San Diego researchers receive new CIRM funding 2Health News:UC San Diego researchers receive new CIRM funding 3Health News:Inherited DNA change explains overactive leukemia gene 2Health News:Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture 2
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
Narrow 12 mm jaws with fine teeth. Serrated handle with polished finish....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Straight shafts with delicate 0.7 mm, 1 x 2 teeth. Serrated handle with polished finish....
Medicine Products: